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Avian Influenza (AI) is an infectious disease caused by the influenza type A virus. The highly 
pathogenic AI (HPAI) H5N1 outbreak in Indonesia has occurred since 2003 until now. 
Education, biosecurity, vaccination, elimination, diagnostic, and surveillance are strategy to 
prevent and control AI virus (AIV) infection. Providing antiviral drug can be used as an 
alternative to control AIV in poultry, but it will be limited if resistance occurs. This study aims 
to determine the resistance to neuraminidase inhibitors (NAIs) (oseltamivir) and M2 ion channel 
inhibitors (amantadine) of HPAI H5N1 virus isolated from poultry in Sulawesi during 2017-
2018. This research was conducted by whole-genome sequencing (WGS) with the next 
generation sequencing (NGS) (Illumina) technique on 5 poultry virus isolates. Molecular analysis 
was performed by multiple alignments and amino acid prediction using the MEGA X program. 
Antiviral resistance of oseltamivir and amantadine was assessed based on analysis of NA and 
M2 proteins compared to reference isolates from Sulawesi in NCBI. Based on the NA protein 
analysis, no mutations were found at positions 119, 275, 293, and 295, indicating that all the 
samples and reference isolates from Sulawesi are still sensitive to oseltamivir. Whereas at 
positions 26, 27, 30, 31, and 34 of M2 protein, there was a V27I mutation in Sulawesi reference 
isolate in 2016 and the combination of V27A and S31N mutations in 2 research isolates in 2018, 
which indicate possible resistance to amantadine. In conclusion, there is amantadine resistance 
of HPAI-H5N1 virus isolated from poultry in Sulawesi, 2018.  
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Avian Influenza (AI) is an infectious disease caused by influenza virus type A from the family 
Orthomyxoviridae. AI viruses mainly attack various poultry types such as chickens, turkeys, 
geese, waterfowl, seabirds, and wild birds (Boyce et al., 2009). This virus causes significant 
economic losses, especially in the poultry industry (Pongcharoensuk et al., 2012). Highly 
pathogenic AI (HPAI) H5N1 outbreaks in Indonesia were initially detected on poultry farms in 
December 2003 at several commercial chicken farms in West Java and Central Java (Lam et al., 
2008). HPAI H5N1 outbreaks are still present and detected in various regions in Indonesia 
(Karo-Karo et al., 2019; Wibawa et al., 2018). 
 
Vaccination is a strategy to prevent and control AIV infection in poultry as part of 
comprehensive programme including education, biosecurity, elimination, diagnostic, and 
surveillance (Lee et al., 2011; Swayne, 2012). Vaccination in poultry is challenged by the 
presence of genetic and antigenic divergence of this virus (Nguyen et al., 2013). Antiviral drugs 
is an alternative to AIV control in poultry (Abdelwhab & Hafez, 2015). Two groups of antiviral 
that commonly used to control of influenza viruses in human is neuraminidase inhibitors (NAIs) 
and M2 ion channel inhibitors (adamantine) (Haque & Elzagheid, 2019; Stiver, 2003), both of 
them can also be used as controls of AIV in poultry (Abdelwhab & Hafez, 2015). However, 
antiviral treatment will be limited if resistance occurs (Govorkova et al., 2014). Data regarding 
antiviral resistance to NAIs and adamantine are limited. Meanwhile, there is no report on 
resistance to antivirals of AIV poultry isolates in Sulawesi before. This study aims to determine 
the antiviral resistance of NAIs and adamantine in HPAI-H5N1 virus isolated from poultry in 
Sulawesi, especially in 2017-2018. 
 
Materials and Methods  
 
Isolation and Identification AI Virus                                                                                               
 
In this study, we used 5 samples of isolates from poultry (ducks and chickens). Isolates were 
collections of the Disease Investigation Center Maros (DIC Maros) originating from cases of 
poultry disease outbreaks and AI disease surveillance in various regions in Sulawesi in 2017-
2018. Samples were taken from oropharyngeal swabs and organs presenting symptoms of illness 
or death. Then the isolation was carried out on chicken embryos and identified positive AI virus 
H5 based on the OIE procedure (OIE, 2018). 
 
Sequencing and Molecular Analysis 
 
The isolates were sent and sequenced at the National Reference Laboratory for AI disease, 
Disease Investigation Center Wates (DIC Wates), Yogyakarta. Sequencing was carried out for 
whole-genome sequencing (WGS) with the next-generation sequencing (NGS) technique. The 
WGS procedure is the same as that used by Lestari et al. (Lestari et al., 2020). WGS AI virus is 
carried out based on the multisegment RT-PCR (mRT-PCR) method, which amplifies all eight 
segments of the AI virus simultaneously by using a pair of primers that adhere to and initiate 
the polymerization process of the conserved region of the AI virus promoter (Zhou et al., 
2009). The validation and sequencing of nucleotides were carried out using the CLC Genomic 
Workbench. Furthermore, the assembly is carried out by using the de-novo assembly technique. 
Contiq from the assembly results then BLAST on the database at NCBI (NCBI / 
www.ncbi.nlm.nih.gov). The trimmed sequence is then mapped to a selected reference and 
extracted into a FASTA file. FASTA files of NA and M genes were then analyzed for nucleotides 
and amino acids. 
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Nucleotide sequence data for NA and M genes obtained were then performed multiple 
alignments with reference isolates from Sulawesi using the Muscle program in MEGA X software 
(http://www.megasoftware.net). Nucleotide sequences of NA and M genes were translated for 
the prediction of NA and M2 proteins. NA protein is encoded from nucleotide positions 21-
1430, while M2 protein begins with a start codon at positions 11-36 and ends with a stop codon 
at positions 725-992. References isolates from Sulawesi are isolated AI virus Sulawesi from 2005 
to 2016 in the National Center for Biotechnology Information (NCBI / www.ncbi.nlm.gov) 
database by selecting one isolate per year for the same district. 
 
Results and Discussions 
 
In antiviral treatment for influenza, there are two main groups, namely: NAIs and adamantine 
(Haque & Elzagheid, 2019; Stiver, 2003). Two antiviral including neuraminidase inhibitors, 
namely oseltamivir, and zanamivir. The mechanism of action of NAIs is to inhibit the viral 
neuraminidase enzyme. The virus that has replicated in the cell will stick to the inner wall of 
the cell membrane. Neuraminidase is needed by the virus that has been formed to get out of 
the cell. Because neuraminidase is inhibited, the virus cannot escape from the cell (Stiver, 2003). 
Meanwhile, two drugs belonging to the adamantine class are amantadine and rimantadine 
(Galvao et al., 2014; Stiver, 2003) with antiviral mechanism by blocking the M2 channel in the 
influenza A virus and inhibit the last stage when the virus will enter (Richman & Nathanson, 
2016).  
 
Table 1. NA antiviral resistance marker of HPAI H5N1 
No Isolate NA Antiviral Resistance Marker 
119 275 293 295 
1. A/Goose/Guangdong/1/96(H5N1) E H R N 
2. A/chicken/Sulawesi Selatan/UT2093/2005(H5N1) . . . . 
3. A/duck/Parepare/BBVM/2005(H5N1) . . . . 
4. A/duck/Sidrap/07160336-3/2016(H5N1) . . . . 
5. A/chicken/Luwu Timur/07171285-7/2017(H5N1)* . . . . 
6. A/chicken/Sidenreng Rappang/A0718004-
2/2018(H5N1)* 
. . . . 
7. A/chicken/Jeneponto/A07180071-7/2018(H5N1)* . . . . 
8. A/duck/Minahasa Tenggara/A07180077-
8/2018(H5N1)* 
. . . . 
9. A/duck/Sidenreng Rappang/A07180110-11/2018(H5N1)* . . . . 
Note: (*) is the isolate being studied 
 
Amino acids at positions 119, 275, 293, and 295 are NA antiviral resistance markers with E119, 
H275, R293, and N295 indicating viral sensitivity to oseltamivir (El-Shesheny et al., 2014). 
E119V NA mutations contribute to increased oseltamivir resistance in humans and waterfowl. 
However, the E119V NA mutation did not cause permanent oseltamivir resistance in poultry 
(Achenbach & Bowen, 2013; Hewajuli & Dharmayanti, 2019). In an experimental study,                                                   
multidrug resistance of NAIs (oseltamivir, zanamivir, and peramivir) was found in HPAI H5N1, 
namely the E119D substitution and the E119A/D/G-H274Y substitution combination (N2 
numbering) (Baek et al., 2015). The H275Y mutation causes resistance to oseltamivir and causes 
a fourfold decrease in sensitivity (Zaraket et al., 2014). Resistance to NAIs has also been reported 
in Vietnam with mutations E119G, H274Y, R292K, and N295S (N2 numbering) in HPAI H5N1 
patients (de Jong et al., 2005). 
 
The position of the amino acids for the NA antiviral resistance marker on the isolates of this 
study can be seen in Table 1. In this study, the entire sample studied and also the reference 
sample from Sulawesi showed amino acids E119, H275, R293, and N295, which means that all 
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samples from Sulawesi from 2005 to 2018 still shows sensitivity to oseltamivir. In the previous 
study by Wibawa et al. (2018) amino acids E119, H275, and N295 have been found in poultry 
isolates in 2016 from Indonesia. The sensitivity of oseltamivir based on amino acid positions 
E119, H275, R293, and N295 has also been reported in duck isolates in Indonesia (Lestari et 
al., 2020). 
 
Table 2. M2 antiviral resistance marker of HPAI H5N1 
No Isolate M2 Antiviral Resistance Marker 
26 27 30 31 34 
1. A/Goose/Guangdong/1/96(H5N1) L V A S G 
2. A/chicken/Wajo/BBVM/2005(H5N1) . . . . . 
3. A/duck/Parepare/BBVM/2005(H5N1) . . . . . 
4. A/chicken/Sulsel/UT2093/2005(H5N1) . . . . . 
5. A/chicken/Mamuju/BBVM-1/2007(H5N1) . . . . . 
6. A/chicken/Palopo/BBVM-1/2007(H5N1) . . . . . 
7. A/chicken/Pare_Pare/BBVM-1/2007(H5N1) . . . . . 
8. A/chicken/Pinrang/BBVM-1/2007(H5N1) . . . . . 
9. A/chicken/Indonesia/Soppeng1631-71/2007(H5N1) . . . . . 
10. A/chicken/Majene/613/2008(H5N1 . . . . . 
11. A/chicken/Mamuju/645/2008(H5N1 . . . . . 
12. A/chicken/Maros/BBVM-1/2008(H5N1) . . . . . 
13. A/chicken/Sidrap/BBVM-1/2008(H5N1) . . . . . 
14. A/chicken/Maros/36/2009(H5N1) . . . . . 
15. A/chicken/Jeneponto/69/2009(H5N1) . . . . . 
16. A/chicken/Pangkep/88/2009(H5N1) . . . . . 
17. A/chicken/Parepare/133/2009(H5N1) . . . . . 
18. A/chicken/Sidrap/40/2009(H5N1) . . . . . 
19. A/chicken/Soppeng/18/2009(H5N1) . . . . . 
20. A/duck/Sidrap/07160336-3/2016(H5N1) . I . . . 
21. A/chicken/Luwu_Timur/07171285-7/2017(H5N1)* . . . . . 
22. A/duck/Sidenreng Rappang/A07180004-2/2018(H5N1)* . . . . . 
23. A/chicken/Janeponto/A07180071-7/2018(H5N1)* . A . N . 
24. A/duck/Minahasa_Tenggara/A07180077-
8/2018(H5N1)* 
. A . N . 
25. A/duck/Sidenreng_Rappang/A07180110-
11/2018(H5N1)* 
. . . . . 
Note: (*) is the isolate being studied 
 
The spread of adamantine resistance is reported to vary among HA subtypes, host species, 
isolation period, and region (Hewajuli & Dharmayanti, 2019). The amino acid residues of M2 
L26, V27, A30, S31, and G34 are associated with amantadine sensitivity (El-Shesheny et al., 
2014; Pinto et al., 1992). Meanwhile, mutations in L26I, V27A/Y/I, G34D/E, and A30T/V are 
associated with resistance to amantadine (El-Shesheny et al., 2014). In this study, the resistance 
to adamantine can be seen in Table 2. We found a V271I mutation and a combination of V27A 
and S31N mutations. The V27I mutation was found in isolate A/duck/Sidenrang Rappang/ 
07160336-3/2016 and the combination of V27A and S31N mutations were found in 2 isolates, 
namely isolates A/chicken/Jeneponto/A07180071-7/2018 and A/duck/Minahasa Tenggara/ 
A07180077-8/2018. The V27I mutation was reported by Dharmayanti et al. (2013) in the 
outbreak case of duck AI virus subtype H5N1 clade 2.3.2. These mutations were also found in 
the research of Lestari et al. (2020) and Wibawa et al. (2018). The mutation in V27I is unique, 
whereas the mutation at amino acid position 27 is V27A usually present. The occurrence of 
unique V27I substitution on M2 protein may influence the resistance of AI virus subtype H5N1 
clade 2.3.2 to amantadine (Hewajuli, 2017; Hewajuli & Dharmayanti, 2019). V27A and S31N 
mutations are similar to the M2 protein mutations of group B isolate that are reassortant in the 
PB2 + MP + NS gene in the research of Wibawa et al. (2018), which explained that they may 
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be more resistant to amantadine treatment. AI viruses isolated in Indonesia in 2003-2008 had 
a V27A or S31N mutation of 66.328% (91/146) and were resistant to amantadine, while 10 
isolates experienced a combination of V27A and S31N mutations. Single or multiple mutations 




From this study, we revealed that based on the NA protein analysis, there were no mutations 
at the 119, 275, 293, and 295 positions which indicated that all of the research samples and 
other Sulawesi isolates were still sensitive to oseltamivir. Whereas in M2 protein there was a 
V27I mutation in Sulawesi reference isolate in 2016 in NCBI as well as a combination of V27A 
and S31N mutations in 2 research isolates in 2018, which indicates the possibility of resistance 
to amantadine. We concluded that there is amantadine resistance of HPAI-H5N1 virus isolated 
from poultry in Sulawesi, 2018. 
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